Publications

2017

  1. Belknap R, Holland D, Feng PJ, Millet JP, Caylà JA, Martinson NA, Wright A, Chen MP, Moro RN, Scott NA, Arevalo B, Miró JM, Villarino ME, Weiner M, Borisov AS; TB Trials Consortium iAdhere Study Team. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial. Ann Intern Med. 2017 Nov 7. [Epub ahead of print] PMID: 29114781

  2. Huaman MA, Ticona E, Miranda G, Kryscio RJ, Mugruza R, Aranda E, Rondan P, Henson D, Ticona C, Sterling TR, Fichtenbaum C, Garvy BA. The Relationship between Latent Tuberculosis Infection and Acute Myocardial Infarction. Clin Infect Dis. 2017 Oct 21. [Epub ahead of print]. PMID: 29069328

  3. Ashley RE, Blower TR, Berger JM, Osheroff N. Recognition of DNA Supercoil Geometry by Mycobacterium tuberculosis Gyrase. Biochemistry. 2017 Oct 10;56(40):5440-5448. Epub 2017 Sep 25. PMCID: PMC5637011

  4. van der Heijden YF, Karim F, Mufamadi G, Zako L, Chinappa T, Shepherd BE, Maruri F, Moosa MS, Sterling TR, Pym AS. Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa. Int J Tuberc Lung Dis. 2017 Jun 1;21(6):670-676. PMCID: PMC5536436

  5. Rockwood N, Costa DL, Amaral EP, Bruyn ED, Kubler A, Gil-Santana L, Fukutani KF, Scanga CA, Flynn JL, Jackson SH, Wilkinson KA, Bishai WR, Sher A, Wilkinson RJ, Andrade BB. Mycobacterium tuberculosis induction of heme oxygenase-1 expression is dependent on oxidative stress and reflects treatment outcomes. Front Immunol. 2017 May 12. PMCID: PMC5427075

  6. ​Prada-Medina CA, Fukutani KF, Pavan Kumar N, Gil-Santana L, Babu S, Lichtenstein F, West K, Sivakumar S, Menon PA, Viswanathan V, Andrade BB, Nakaya HI, Kornfeld H. Systems Immunology of Diabetes-Tuberculosis Comorbidity Reveals Signatures of Disease Complications. Sci Rep. 2017 May 17;7(1):1999. PMCID: PMC5435727

  7. ​Huaman MA, Kryscio RJ, Fichtenbaum CJ, Henson D, Salt E, Sterling TR, Garvy BA. Tuberculosis and risk of acute myocardial infarction: a propensity score-matched analysis. Epidemiol Infect. 2017 May;145(7):1363-1367. PMID: 28202093

  8. ​Bordelon H, Ricks KM, Pask ME, Russ PK, Solinas F, Baglia ML, Short PA, Nel A, Blackburn J, Dheda K, Zamudio C, Cáceres T, Wright DW, Haselton FR, Pettit AC. Design and use of mouse control DNA for DNA biomarker extraction and PCR detection from urine: Application for transrenal Mycobacterium tuberculosis DNA detection. J Microbiol Methods. 2017 May;136:65-70. PMID: 28285168

  9. Moro RN, Sterling TR, Saukkonen J, Vernon A, Horsburgh CR, Chaisson RE, Hamilton CD, Villarino ME, Goldberg S. Factors associated with non-completion of follow-up: 33-month latent tuberculous infection treatment trial. Int J Tuberc Lung Dis. 2017 Mar 1;21(3):286-296. PMID: 28087928

  10. McAnaw SE, Hesseling AC, Seddon JA, Dooley KE, Garcia-Prats AJ, Kim S, Jenkins HE, Schaaf HS, Sterling TR, Horsburgh CR. Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities. Int J Infect Dis. 2017 Mar;56:194-199. PMID: 27955992

  11. Carlucci JG, Blevins M, Kipp AM, Lindegren ML, Du QT, Renner L, Reubenson G, Ssali J, Yotebieng M, Mandalakas AM, Davies MA, Ballif M, Fenner L, Pettit AC; International Epidemiology Databases to Evaluate AIDS (IeDEA) Network. Tuberculosis Treatment Outcomes among HIV/TB Co-Infected Children in the International Epidemiology Databases to Evaluate AIDS (IeDEA) Network. J Acquir Immune Defic Syndr. 2017 Feb 20. PMID: 28234689

  12. Clouse K, Blevins M, Lindegren ML, Yotebieng M, Nguyen DT, Omondi A, Michael D, Zannou DM, Carriquiry G, Pettit AC. Low Implementation of Xpert MTB/RIF Among HIV/TB Co-Infected Adults in the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Program. PLoS One. 2017 Feb 9;12(2):e0171384. PMID: 28182705

  13. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, O'Brien RJ, Pai M, Richeldi L, Salfinger M, Shinnick TM, Sterling TR, Warshauer DM, Woods GL. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2017 Jan 15;64(2):111-115. PMID: 28052967

2016

  1. Sterling TR. Fluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016 Dec 1;20(12):42-47. PMID: 28240572

  2. Eilertson B, Maruri F, Blackman A, Herrera M, Sterling TR. Reversion of phenotypic fluoroquinolone resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2016 Sep;20(9):1276-7. PMID: 27510259.

  3. Eilertson B, Maruri F, Blackman A, Guo Y, Herrera M, van der Heijden Y, Shyr Y, Sterling TR. A novel resistance mutation in eccC5 of the ESX-5 secretion system confers ofloxacin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2016 Sep;71(9):2419-27. PMCID: PMC4992850

  4. ​Buchacz K, Lau B, Jing Y, Bosch R, Abraham AG, Gill MJ, Silverberg MJ, Goedert JJ, Sterling TR, Althoff KN, Martin JN, Burkholder G, Gandhi N, Samji H, Patel P, Rachlis A, Thorne JE, Napravnik S, Henry K, Mayor A, Gebo K, Gange SJ, Moore RD, Brooks JT; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010. J Infect Dis. 2016 Sep 15;214(6):862-72. PMID: 27559122

  5. Pettit AC, Mendes A, Jenkins C, Napravnik S, Freeman A, Shepherd BE, Dowdy D, Gill J, Rachlis A, Moore R, Sterling TR; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) investigators of International epidemiologic Databases to Evaluate AIDS (IeDEA). Timing of Antiretroviral Treatment, Immunovirologic Status, and TB Risk: Implications for Testing and Treatment. J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):572-8. PMCID: PMC4942351.

  6. Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, Chen MP, Benator DA, Gordin F, Benson CA, Chaisson RE, Villarino ME; Tuberculosis Trials Consortium, the AIDS Clinical Trials Group for the PREVENT TB Trial (TBTC Study 26ACTG 5259) Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS. 2016 Jun 19;30(10):1607-15. PMID: 27243774

  7. Moro RN, Borisov AS, Saukkonen J, Khan A, Sterling TR, Villarino ME, Scott NA, Shang N, Kerrigan A, Goldberg SV. Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada. Clin Infect Dis. 2016 Jun 1;62(11):1390-400. PMID: 26951571.

  8. Charles MK, Lindegren ML, Wester CW, Blevins M, Sterling TR, Dung NT, Dusingize JC, Avit-Edi D, Durier N, Castelnuovo B, Nakigozi G, Cortes CP, Ballif M, Fenner L; International epidemiology Databases to Evaluate AIDS (IeDEA) Collaboration. Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries. PLoS One. 2016 Apr 13;11(4):e0153243. PMCID: PMC4830552.

  9. Villegas L, Otero L, Sterling TR, Huaman MA, Van der Stuyft P, Gotuzzo E, Seas C. Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin-Mono-Resistant Pulmonary Tuberculosis in Lima, Peru. PLoS One. 2016 Apr 5;11(4):e0152933. PMCID: PMC4821555

  10. Pettit AC, Mendes A, Jenkins C, Napravnik S, Freeman A, Shepherd BE, Dowdy D, Gill J, Rachlis A, Moore R, Sterling TR; NA-ACCORD investigators of International epidemiologic Databases to Evaluate AIDS (IeDEA). Timing of Antiretroviral Treatment, Immunovirologic Status and TB Risk: Implications for Test and Treat.  J Acquir Immune Defic Syndr. 2016 Apr 5. [Epub ahead of print] PMID: 27049511

  11. Aldred KJ, Blower TR, Kerns RJ, Berger JM, Osheroff N. Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase. Proc Natl Acad Sci USA. 2016 Jan 20. pii: 201525055. [Epub ahead of print] PMID:26792518

2015

  1. Huaman MA, Henson D, Ticona E, Sterling TR, Garvy BA. Tuberculosis and Cardiovascular Disease: Linking the Epidemics. Trop Dis Travel Med Vaccines. 2015;1. pii: 10. Epub 2015 Oct 30. PMCID: PMC4729377.

  2. Hamilton CD, Swaminathan A, Christopher D, Ellner J, Gupta A, Sterling TR, Rolla V, Srinivasan S, Karyana M, Siddiqui A, Stoszek SK, Kim P. RePORT International: Advancing Tuberculosis Biomarker Research Through Global Collaboration. Clin Infect Dis. 2015 Oct 15;61Suppl 3:S155-9. PMID: 26409277

  3. Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, Cavalcante S, Cedillos R, Chaisson R, Chee CB, Chesire L, Corbett E, Dara M, Denholm J, de Vries G, Falzon D, Ford N, Gale-Rowe M, Gilpin C, Girardi E, Go UY, Govindasamy D, Grant AD, Grzemska M, Harris R, Horsburgh CR Jr, Ismayilov A, Jaramillo E, Kik S, Kranzer K, Lienhardt C, LoBue P, Lönnroth K, Marks G, Menzies D, Migliori GB, Mosca D, Mukadi YD, Mwinga A, Nelson L, Nishikiori N, Oordt-Speets A, Rangaka MX, Reis A, Rotz L, Sandgren A, Sañé Schepisi M, Schünemann HJ, Sharma SK, Sotgiu G, Stagg HR, Sterling TR, Tayeb T, Uplekar M, van der Werf MJ, Vandevelde W, van Kessel F, Van't Hoog A, Varma JK, Vezhnina N, Voniatis C, Vonk Noordegraaf-Schouten M, Weil D, Weyer K, Wilkinson RJ, Yoshiyama T, Zellweger JP, Raviglione M. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015 Sep 24. pii: ERJ-01245-2015. PMID:26405286

  4. Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME; TB Trials Consortium. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int J Tuberc Lung Dis. 2015 Sep;19(9):1039-44. PMID: 26260821

  5. Sterling TR. Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment. Evid Based Med. 2015 Aug;20(4):128-9. PMID: 25926523

  6. Sterling TR, Moro RN, Borisov AS, Phillips E, Shepherd G, Adkinson NF, Weis S, Ho C, Villarino ME; TB Trials Consortium. Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT TB Study. Clin Infect Dis. Aug 2015; 61(4): 527-35. PMID: 25904367

  7. Creecy A, Russ PK, Solinas F, Wright DW, Haselton FR. Tuberculosis Biomarker Extraction and Isothermal Amplification in an Integrated Diagnostic Device. PLoS One. 2015 Jul 1;10(7):e0130260. PMID: 26132307

  8. van der Heijden YF, Heerman WJ, McFadden S, Zhu Y, Patterson, B. (2015). Missed Opportunities for Tuberculosis Screening in Primary Care. Journal of Pediatrics. 2015 May; 166(5): 1240-5. PMCID: PMC4414729

  9. van der Heijden YF, Maruri F, Holt E, Mitchel E, Warkentin J, Sterling TR. (2015). A Comparison of Interview Methods to Ascertain Fluoroquinolone Exposure Before Tuberculosis Diagnosis. Epidemiology and Infection. 2015 Apr; 143(5), 960-5. PMCID: PMC4352378

  10. Huaman MA, Fiske CT, Jones TF, Warkentin J, Shepherd BE, Ingram LA, Maruri F, Sterling TR. Tuberculosis and the risk of infection with other intracellular bacteria: a population-based study. Epidemiol Infect. 2015 Apr;143(5):951-9. PMCID: PMC4336842

  11. Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; IMPAACT, TB Trials Consortium. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015 Mar; 169(3):247-55. PMID: 25580725

2014

  1. Eilertson B, Maruri F, Blackman A, Herrera M, Samuels DC, Sterling TR. High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother. 2014; 58(6):3270-5. PMCID: PMC4068501.

  2. Ballif M, Nhandu V, Wood R, Dusingize JC, Carter EJ, Cortes CP, McGowan CC, Diero L, Graber C, Renner L, Hawerlander D, Kiertiburanakul S, Du QT, Sterling TR, Egger M, Fenner L; International epidemiological Databases to Evaluate AIDS (IeDEA). Detection and management of drug-resistant tuberculosis in HIV-infected patients in lower-income countries. Int J Tuberc Lung Dis. 2014 Nov;18(11):1327-36. PMID: 25299866

  3. Menzies D, Sterling TR. Treatment of Mycobacterium tuberculosis infection: time to get a move on? Ann Intern Med. 2014 Sep 16;161(6):449-50. PMID: 25111391

  4. Weiner M, Savic RM, Kenzie WR, Wing D, Peloquin CA, Engle M, Bliven E, Prihoda TJ, Gelfond JA, Scott NA, Abdel-Rahman SM, Kearns GL, Burman WJ, Sterling TR, Villarino ME. Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly With Rifapentine and Isoniazid for Latent Tuberculosis Infection. J Pediatric Infect Dis Soc. 2014 Jun;3(2):132-45. PMID:  26625366

  5. Fiske CT, Yan FX, Hirsch-Moverman Y, Sterling TR, Reichler MR; Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Risk factors for treatment default in close contacts with latent tuberculous infection. Int J Tuberc Lung Dis. 2014 Apr;18(4):421-7.

2013

  1. Huaman MA, Sterling TR, Shepherd BE, Fiske CT. 25-Hydroxyvitamin D levels after recovery from tuberculosis: Insights into pathogenesis. Tuberculosis (Edinb). 2013 Nov 6. pii: S1472-9792(13)00191-1.
  2. Shepardson D, Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, Tian X, Borisov AS, Shang N, Heilig CM, Sterling TR, Villarino ME, Mac Kenzie WR. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. Int J Tuberc Lung Dis. 2013 Dec;17(12):1531-7. PMID: 24200264

  3. Person AK, Pettit AC, Sterling TR. Diagnosis and treatment of latent tuberculosis infection: an update. Curr Respir Care Rep. 2013 Dec; 2(4):199-207. PMCID: PMC4185413

  4. van der Heijden YF, Maruri F, Blackman A, et al. Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones. Int. J. Antimicrob. Agents. Sep 2013;42(3):232-237.
  5. Chang KC, Sterling TR, Yew WW. Are we ready to shorten the treatment duration for non-cavitary pulmonary tuberculosis? Int J Tuberc Lung Dis. 2013 Jun;17(6):712. PMID: 23676152

  6. Shepherd BE, Jenkins CA, Parrish DD, Glass TR, Cescon A, Masabeu A, Chene G, de Wolf F, Crane HM, Jarrin I, Gill J, del Amo J, Abgrall S, Khaykin P, Lehmann C, Ingle SM, May MT, Sterne JA, Sterling TR. Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis. AIDS. 2013 May 15;27(8):1321-9. PMCID: PMC3992322

  7. Pettit AC, Cummins J, Kaltenbach LA, Sterling TR, Warkentin JV. Non-adherence and drug-related interruptions are risk factors for delays in completion of treatment for tuberculosis. Int. J. Tuberc. Lung Dis. Apr 2013;17(4):486-492.
  8. Pettit AC, Bethel J, Hirsch-Moverman Y, Colson PW, Sterling TR. Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. J. Infect. Nov 2013;67(5):424-432.
  9. Bordelon H, Russ PK, Wright DW, Haselton FR. A magnetic bead-based method for concentrating DNA from human urine for downstream detection. PLoS One. 2013;8(7):e68369.

2012

  1. van der Heijden YF, Maruri F, Blackman A, et al. Fluoroquinolone exposure prior to tuberculosis diagnosis is associated with an increased risk of death. Int. J. Tuberc. Lung Dis. Sep 2012;16(9):1162-1167.
  2. Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001270.
  3. Person AK, Sterling TR. Treatment of latent tuberculosis infection in HIV: shorter or longer? Curr HIV/AIDS Rep. Sep 2012;9(3):259-266.
  4. Oswald-Richter KA, Beachboard DC, Seeley EH, et al. Dual analysis for mycobacteria and propionibacteria in sarcoidosis BAL. J. Clin. Immunol. Oct 2012;32(5):1129-1140.
  5. Maruri F, Sterling TR, Kaiga AW, et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J. Antimicrob. Chemother. Apr 2012;67(4):819-831.
  6. Kernodle DS. Warning: differences in the copy number of duplication unit 2 (DU2) within BCG Danish 1331 may influence findings involving genetically modified BCG Danish strains. Vaccine. Sep 14 2012;30(42):6013-6014; author reply 6015.
  7. Kernodle DS. SigH, antioxidants, and the pathogenesis of pulmonary tuberculosis. J. Infect. Dis. Apr 15 2012;205(8):1186-1188.
  8. Hiatt LA, Cliffel DE. Real-time Recognition of Mycobacterium tuberculosis and Lipoarabinomannan using the Quartz Crystal Microbalance. Sens. Actuators B Chem. Nov 1 2012;174:245-252.
  9. Fiske CT, Griffin MR, Mitchel E, Sterling TR, Grijalva CG. Accuracy of pharmacy and coded-diagnosis information in identifying tuberculosis in patients with rheumatoid arthritis. Pharmacoepidemiol. Drug Saf. Jun 2012;21(6):666-669.
  10. Fiske CT, de Almeida AS, Shintani AK, Kalams SA, Sterling TR. Abnormal immune responses in persons with previous extrapulmonary tuberculosis in an in vitro model that simulates in vivo infection with Mycobacterium tuberculosis. Clin. Vaccine Immunol. Aug 2012;19(8):1142-1149.
  11. de Almeida AS, Fiske CT, Sterling TR, Kalams SA. Increased frequency of regulatory T cells and T lymphocyte activation in persons with previously treated extrapulmonary tuberculosis. Clin. Vaccine Immunol. Jan 2012;19(1):45-52.
  12. Blackman A, May S, Devasia RA, Maruri F, Stratton C, Sterling TR. Microcolonies in fluoroquinolone agar proportion susceptibility testing of Mycobacterium tuberculosis: an indicator of drug resistance. Eur. J. Clin. Microbiol. Infect. Dis. Sep 2012;31(9):2177-2182.

2011

  1. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N. Engl. J. Med. Dec 8 2011;365(23):2155-2166.
  2. Sterling TR, Lau B, Zhang J, et al. Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J. Infect. Dis. Sep 15 2011;204(6):893-901.
  3. Pettit AC, Kaltenbach LA, Maruri F, et al. Chronic lung disease and HIV infection are risk factors for recurrent tuberculosis in a low-incidence setting. Int. J. Tuberc. Lung Dis. Jul 2011;15(7):906-911.
  4. Pettit AC, Jenkins CA, Stinnette SE, et al. Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting? J. Acquir. Immune Defic. Syndr. Aug 1 2011;57(4):305-310.
  5. Murphree R, Warkentin JV, Dunn JR, Schaffner W, Jones TF. Elephant-to-human transmission of tuberculosis, 2009. Emerg. Infect. Dis. Mar 2011;17(3):366-371.
  6. Manier ML, Reyzer ML, Goh A, et al. Reagent precoated targets for rapid in-tissue derivatization of the anti-tuberculosis drug isoniazid followed by MALDI imaging mass spectrometry. J. Am. Soc. Mass Spectrom. Aug 2011;22(8):1409-1419.
  7. Kipp AM, Pungrassami P, Stewart PW, Chongsuvivatwong V, Strauss RP, Van Rie A. Study of tuberculosis and AIDS stigma as barriers to tuberculosis treatment adherence using validated stigma scales. Int. J. Tuberc. Lung Dis. Nov 2011;15(11):1540-1545, i.
  8. Kipp AM, Pungrassami P, Nilmanat K, et al. Socio-demographic and AIDS-related factors associated with tuberculosis stigma in southern Thailand: a quantitative, cross-sectional study of stigma among patients with TB and healthy community members. BMC Public Health. 2011;11:675.
  9. Bukka A, Price CT, Kernodle DS, Graham JE. Mycobacterium tuberculosis RNA Expression Patterns in Sputum Bacteria Indicate Secreted Esx Factors Contributing to Growth are Highly Expressed in Active Disease. Front Microbiol. 2011;2:266.

2010

  1. Sterling TR, Pham PA, Chaisson RE. HIV infection-related tuberculosis: clinical manifestations and treatment. Clin. Infect. Dis. May 15 2010;50 Suppl 3:S223-230.
  2. Oswald-Richter KA, Drake WP. The etiologic role of infectious antigens in sarcoidosis pathogenesis. Semin. Respir. Crit. Care Med. Aug 2010;31(4):375-379.
  3. Oswald-Richter KA, Beachboard DC, Zhan X, et al. Multiple mycobacterial antigens are targets of the adaptive immune response in pulmonary sarcoidosis. Respir. Res. 2010;11:161.
  4. Motsinger-Reif AA, Antas PR, Oki NO, Levy S, Holland SM, Sterling TR. Polymorphisms in IL-1beta, vitamin D receptor Fok1, and Toll-like receptor 2 are associated with extrapulmonary tuberculosis. BMC Med. Genet. 2010;11:37.
  5. Light RW. Update on tuberculous pleural effusion. Respirology. Apr 2010;15(3):451-458.
  6. Kernodle DS. Decrease in the effectiveness of Bacille Calmette-Guerin vaccine against pulmonary tuberculosis: a consequence of increased immune suppression by microbial antioxidants, not overattenuation. Clin. Infect. Dis. Jul 15 2010;51(2):177-184.
  7. Kazi AM, Shah SA, Jenkins CA, Shepherd BE, Vermund SH. Risk factors and prevalence of tuberculosis, human immunodeficiency virus, syphilis, hepatitis B virus, and hepatitis C virus among prisoners in Pakistan. Int. J. Infect. Dis. Sep 2010;14 Suppl 3:e60-66.
  8. Fiske CT, Griffin MR, Erin H, et al. Black race, sex, and extrapulmonary tuberculosis risk: an observational study. BMC Infect. Dis. 2010;10:16.
  9. Chambers IR, Cone TR, Oswald-Richter K, Drake WP. Enzyme-linked immunospot assay (ELISPOT): Quantification of Th-1 cellular immune responses against microbial antigens. J Vis Exp. 2010(45).